Literature DB >> 28100396

Small molecules remain on target for c-Myc.

Linchong Sun1, Ping Gao1.   

Abstract

Targeting the transcription factor c-Myc via one of its coactivator proteins is a promising strategy for cancer therapy.

Entities:  

Keywords:  Reproducibility Project: Cancer Biology; bromodomain inhibitor; cancer biology; human; metascience; mouse; myeloma; replication; reproducibility

Mesh：

Substances：

Year:  2017        PMID： 28100396      PMCID： PMC5245958          DOI： 10.7554/eLife.22915

Source DB:  PubMed          Journal:  Elife        ISSN： 2050-084X            Impact factor:   8.140


  15 in total

1.  A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth.

Authors:  Sébastien Bonnet; Stephen L Archer; Joan Allalunis-Turner; Alois Haromy; Christian Beaulieu; Richard Thompson; Christopher T Lee; Gary D Lopaschuk; Lakshmi Puttagunta; Sandra Bonnet; Gwyneth Harry; Kyoko Hashimoto; Christopher J Porter; Miguel A Andrade; Bernard Thebaud; Evangelos D Michelakis
Journal:  Cancer Cell       Date:  2007-01       Impact factor: 31.743

Review 2.  Small-molecule inhibitors of the Myc oncoprotein.

Authors:  Steven Fletcher; Edward V Prochownik
Journal:  Biochim Biophys Acta       Date:  2014-03-19

3.  BET bromodomain inhibition as a therapeutic strategy to target c-Myc.

Authors:  Jake E Delmore; Ghayas C Issa; Madeleine E Lemieux; Peter B Rahl; Junwei Shi; Hannah M Jacobs; Efstathios Kastritis; Timothy Gilpatrick; Ronald M Paranal; Jun Qi; Marta Chesi; Anna C Schinzel; Michael R McKeown; Timothy P Heffernan; Christopher R Vakoc; P Leif Bergsagel; Irene M Ghobrial; Paul G Richardson; Richard A Young; William C Hahn; Kenneth C Anderson; Andrew L Kung; James E Bradner; Constantine S Mitsiades
Journal:  Cell       Date:  2011-09-01       Impact factor: 41.582

4.  Nanog requires BRD4 to maintain murine embryonic stem cell pluripotency and is suppressed by bromodomain inhibitor JQ1 together with Lefty1.

Authors:  Gillian A Horne; Helen J S Stewart; Jacqueline Dickson; Stefan Knapp; Bernard Ramsahoye; Timothy Chevassut
Journal:  Stem Cells Dev       Date:  2014-12-17       Impact factor: 3.272

5.  Interaction with WDR5 promotes target gene recognition and tumorigenesis by MYC.

Authors:  Lance R Thomas; Qingguo Wang; Brian C Grieb; Jason Phan; Audra M Foshage; Qi Sun; Edward T Olejniczak; Travis Clark; Soumyadeep Dey; Shelly Lorey; Bethany Alicie; Gregory C Howard; Bryan Cawthon; Kevin C Ess; Christine M Eischen; Zhongming Zhao; Stephen W Fesik; William P Tansey
Journal:  Mol Cell       Date:  2015-03-26       Impact factor: 17.970

6.  Transcriptional amplification in tumor cells with elevated c-Myc.

Authors:  Charles Y Lin; Jakob Lovén; Peter B Rahl; Ronald M Paranal; Christopher B Burge; James E Bradner; Tong Ihn Lee; Richard A Young
Journal:  Cell       Date:  2012-09-28       Impact factor: 41.582

7.  Targeted inhibition of tumor-specific glutaminase diminishes cell-autonomous tumorigenesis.

Authors:  Yan Xiang; Zachary E Stine; Jinsong Xia; Yunqi Lu; Roddy S O'Connor; Brian J Altman; Annie L Hsieh; Arvin M Gouw; Ajit G Thomas; Ping Gao; Linchong Sun; Libing Song; Benedict Yan; Barbara S Slusher; Jingli Zhuo; London L Ooi; Caroline G L Lee; Anthony Mancuso; Andrew S McCallion; Anne Le; Michael C Milone; Stephen Rayport; Dean W Felsher; Chi V Dang
Journal:  J Clin Invest       Date:  2015-04-27       Impact factor: 14.808

8.  Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study.

Authors:  Céline Berthon; Emmanuel Raffoux; Xavier Thomas; Norbert Vey; Carlos Gomez-Roca; Karen Yee; David Christopher Taussig; Keyvan Rezai; Christophe Roumier; Patrice Herait; Carmen Kahatt; Bruno Quesnel; Mauricette Michallet; Christian Recher; François Lokiec; Claude Preudhomme; Hervé Dombret
Journal:  Lancet Haematol       Date:  2016-03-18       Impact factor: 18.959

9.  Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia.

Authors:  Mark A Dawson; Rab K Prinjha; Antje Dittmann; George Giotopoulos; Marcus Bantscheff; Wai-In Chan; Samuel C Robson; Chun-wa Chung; Carsten Hopf; Mikhail M Savitski; Carola Huthmacher; Emma Gudgin; Dave Lugo; Soren Beinke; Trevor D Chapman; Emma J Roberts; Peter E Soden; Kurt R Auger; Olivier Mirguet; Konstanze Doehner; Ruud Delwel; Alan K Burnett; Phillip Jeffrey; Gerard Drewes; Kevin Lee; Brian J P Huntly; Tony Kouzarides
Journal:  Nature       Date:  2011-10-02       Impact factor: 49.962

10.  Replication Study: BET bromodomain inhibition as a therapeutic strategy to target c-Myc.

Authors:  Fraser Aird; Irawati Kandela; Christine Mantis
Journal:  Elife       Date:  2017-01-19       Impact factor: 8.140
View more
  8 in total

1.  Distinct Roles for BET Family Members in Estrogen Receptor α Enhancer Function and Gene Regulation in Breast Cancer Cells.

Authors:  Shino Murakami; Rui Li; Anusha Nagari; Minho Chae; Cristel V Camacho; W Lee Kraus
Journal:  Mol Cancer Res       Date:  2019-09-24       Impact factor: 5.852

Review 2.  Molecules targeting the androgen receptor (AR) signaling axis beyond the AR-Ligand binding domain.

Authors:  N G R Dayan Elshan; Matthew B Rettig; Michael E Jung
Journal:  Med Res Rev       Date:  2018-11-22       Impact factor: 12.944

3.  Mutational landscape of primary, metastatic, and recurrent ovarian cancer reveals c-MYC gains as potential target for BET inhibitors.

Authors:  Charles Li; Elena Bonazzoli; Stefania Bellone; Jungmin Choi; Weilai Dong; Gulden Menderes; Gary Altwerger; Chanhee Han; Aranzazu Manzano; Anna Bianchi; Francesca Pettinella; Paola Manara; Salvatore Lopez; Ghanshyam Yadav; Francesco Riccio; Luca Zammataro; Burak Zeybek; Yang Yang-Hartwich; Natalia Buza; Pei Hui; Serena Wong; Antonella Ravaggi; Eliana Bignotti; Chiara Romani; Paola Todeschini; Laura Zanotti; Valentina Zizioli; Franco Odicino; Sergio Pecorelli; Laura Ardighieri; Dan-Arin Silasi; Babak Litkouhi; Elena Ratner; Masoud Azodi; Gloria S Huang; Peter E Schwartz; Richard P Lifton; Joseph Schlessinger; Alessandro D Santin
Journal:  Proc Natl Acad Sci U S A       Date:  2018-12-24       Impact factor: 11.205

4.  Repression of GCN5 expression or activity attenuates c-MYC expression in non-small cell lung cancer.

Authors:  Lisa Maria Mustachio; Jason Roszik; Aimee T Farria; Karla Guerra; Sharon Yr Dent
Journal:  Am J Cancer Res       Date:  2019-08-01       Impact factor: 6.166

Review 5.  Metabolic reprogramming and epigenetic modifications on the path to cancer.

Authors:  Linchong Sun; Huafeng Zhang; Ping Gao
Journal:  Protein Cell       Date:  2021-05-29       Impact factor: 15.328

6.  Spermine synthase and MYC cooperate to maintain colorectal cancer cell survival by repressing Bim expression.

Authors:  Yubin Guo; Qing Ye; Pan Deng; Yanan Cao; Daheng He; Zhaohe Zhou; Chi Wang; Yekaterina Y Zaytseva; Charles E Schwartz; Eun Y Lee; B Mark Evers; Andrew J Morris; Side Liu; Qing-Bai She
Journal:  Nat Commun       Date:  2020-06-26       Impact factor: 14.919

7.  Induction of GNMT by 1,2,3,4,6-penta-O-galloyl-beta-D-glucopyranoside through proteasome-independent MYC downregulation in hepatocellular carcinoma.

Authors:  Rajni Kant; Chia-Hung Yen; Jung-Hsien Hung; Chung-Kuang Lu; Chien-Yi Tung; Pei-Ching Chang; Yueh-Hao Chen; Yu-Chang Tyan; Yi-Ming Arthur Chen
Journal:  Sci Rep       Date:  2019-02-13       Impact factor: 4.379

8.  The challenges of replication.

Authors: 
Journal:  Elife       Date:  2017-01-19       Impact factor: 8.140
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.